Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) Tax Provisions (2022 - 2024)

Xeris Biopharma Holdings (XERS) has disclosed Tax Provisions for 3 consecutive years, with -$3.3 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Tax Provisions fell 883.43% year-over-year to -$3.3 million, compared with a TTM value of -$3.3 million through Jun 2025, down 789.63%, and an annual FY2024 reading of -$2.3 million, down 81.59% over the prior year.
  • Tax Provisions was -$3.3 million for Q3 2024 at Xeris Biopharma Holdings, down from $749000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $749000.0 in Q2 2024 and bottomed at -$3.3 million in Q3 2024.
  • Average Tax Provisions over 3 years is -$494100.0, with a median of -$338500.0 recorded in 2022.
  • Peak annual rise in Tax Provisions hit 210.96% in 2024, while the deepest fall reached 883.43% in 2024.
  • Year by year, Tax Provisions stood at -$338000.0 in 2022, then skyrocketed by 30.18% to -$236000.0 in 2023, then plummeted by 1308.47% to -$3.3 million in 2024.
  • Business Quant data shows Tax Provisions for XERS at -$3.3 million in Q3 2024, $749000.0 in Q2 2024, and $307000.0 in Q1 2024.